Abstract: Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 ?m and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.

Abstract: Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 ?m and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions.

Abstract: The present disclosure belongs to the technical field of molecular biology, and provides an activator for simultaneously activating oxidative phosphorylation and inhibiting glycolysis and use thereof in preparation of anti-cancer drugs, where the activator is baicalein. The present disclosure has the following beneficial effects: the present disclosure provides an activator for simultaneously activating oxidative phosphorylation and inhibiting glycolysis, that is, baicalein. This activator can activate the oxidative phosphorylation while inhibiting the glycolysis, thereby killing cancer cells. This mechanism can be a new anti-cancer mechanism, and key proteins involved in related pathways can be new targets for drug development.